St. Jude Children's Research Hospital: Excellent Outcomes Reported for First Targeted Frontline Therapy for High-Risk Pediatric Hodgkin Lymphoma
April 08, 2021
April 08, 2021
MEMPHIS, Tennessee, April 8 (TNSOps) -- St. Jude Children's Research Hospital issued the following news release on April 7, 2021:
Scientists are reporting results of the first frontline clinical trial to use targeted therapy to treat high-risk pediatric Hodgkin lymphoma. The study showed that the addition of brentuximab vedotin achieved excellent outcomes, reduced side effects, and allowed for reduced radiation exposures.
The study was the result of work by a mult . . .
Scientists are reporting results of the first frontline clinical trial to use targeted therapy to treat high-risk pediatric Hodgkin lymphoma. The study showed that the addition of brentuximab vedotin achieved excellent outcomes, reduced side effects, and allowed for reduced radiation exposures.
The study was the result of work by a mult . . .